A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115805 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Joo-Young Byun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Penn State College of Medicine, Hershey, PA, USA; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Anaplastic Lymphoma Kinase, Carbazoles. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Penn State College of Medicine, Hershey, PA, USA; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: hyunae.jung@samsung.com.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
Zitieren
APA
Byun, J. Y., Kim, J., Park, S., Sun, J. M., Lee, S. H., Ahn, J. S., Ahn, M. J., Kim, J. H., Lee, E. K., & Jung, H. A. (2025). A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115805
Vancouver
Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, et al. A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115805
BibTeX
@article{Byun2025,
author = {Byun, Joo-Young and Kim, Jinyong and Park, Sehhoon and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Ahn, Myung-Ju and Kim, Ju-Hwan and Lee, Eui-Kyung and Jung, Hyun Ae},
title = {A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115805}
}
EUVIMED